Design and analysis of bridging studies with prior probabilities on the null and alternative hypotheses
Donglin Zeng,
Zhiying Pan and
D. Y. Lin
Biometrics, 2020, vol. 76, issue 1, 224-234
Abstract:
The pharmaceutical industry and regulatory agencies are increasingly interested in conducting bridging studies in order to bring an approved drug product from the original region (eg, United States or European Union) to a new region (eg, Asian‐Pacific countries). In this article, we provide a new methodology for the design and analysis of bridging studies by assuming prior knowledge on how the null and alternative hypotheses in the original, foreign study are related to the null and alternative hypotheses in the bridging study and setting the type I error for the bridging study according to the strength of the foreign‐study evidence. The new methodology accounts for randomness in the foreign‐study evidence and controls the average type I error of the bridging study over all possibilities of the foreign‐study evidence. In addition, the new methodology increases statistical power, when compared to approaches that do not use foreign‐study evidence, and it allows for the possibility of not conducting the bridging study when the foreign‐study evidence is unfavorable. Finally, we conducted extensive simulation studies to demonstrate the usefulness of the proposed methodology.
Date: 2020
References: Add references at CitEc
Citations:
Downloads: (external link)
https://doi.org/10.1111/biom.13175
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:bla:biomet:v:76:y:2020:i:1:p:224-234
Ordering information: This journal article can be ordered from
http://www.blackwell ... bs.asp?ref=0006-341X
Access Statistics for this article
More articles in Biometrics from The International Biometric Society
Bibliographic data for series maintained by Wiley Content Delivery ().